J. Flaim

发表

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

D. Gaudet, F. Raal, R. Santos, 2010, The Lancet.

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

F. Akdim, D. Tribble, Joann D Flaim, 2011, European heart journal.

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.

F. Akdim, D. Tribble, Joann D Flaim, 2010, The American journal of cardiology.

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

Lawrence A Leiter, A. Gotto, M. Banach, 2020, JAMA cardiology.

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

W. Cromwell, Joann D Flaim, G. Thomas, 2013, Journal of the American College of Cardiology.

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

J. Jukema, E. Sijbrands, M. Trip, 2010, Journal of the American College of Cardiology.

Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers

P. Ridker, Joann D Flaim, E. Stroes, 2014, Journal of the American Heart Association.

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

M. Trip, F. Akdim, D. Tribble, 2010, Journal of the American College of Cardiology.

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

J. Kastelein, Joann D Flaim, B. Baker, 2014, Journal of the American Heart Association.

An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency

D. Gaudet, K. Tremblay, R. Geary, 2014 .

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-—O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

D. Tribble, Joann D Flaim, R. Yu, 2009, Clinical pharmacokinetics.

The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

D. Gaudet, Joann D Flaim, L. Hemphill, 2017, Atherosclerosis.

AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE

D. Gaudet, R. Geary, W. Cheng, 2014 .